Your browser doesn't support javascript.
loading
Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials.
Cuer, Benjamin; Conroy, Thierry; Juzyna, Beata; Gourgou, Sophie; Mollevi, Caroline; Touraine, Célia.
Afiliação
  • Cuer B; Biometrics Unit, Montpellier Cancer Institute, 208, avenue des Apothicaires, 34298, Montpellier, France. cuerbenjamin@gmail.com.
  • Conroy T; French National Platform Quality of Life and Cancer, Montpellier, France. cuerbenjamin@gmail.com.
  • Juzyna B; Institute of Cancer Research of Montpellier (Inserm 1194), ICM, University of Montpellier, Montpellier, France. cuerbenjamin@gmail.com.
  • Gourgou S; Institut de Cancérologie de Lorraine, Department of Medical Oncology, Vandoeuvre-lès-Nancy, France.
  • Mollevi C; APEMAC (Équipe MICS), Université de Lorraine, Nancy, France.
  • Touraine C; French Federation of Comprehensive Cancer Centres, R&D UNICANCER, Paris, France.
Qual Life Res ; 31(5): 1359-1370, 2022 May.
Article em En | MEDLINE | ID: mdl-34817733
ABSTRACT

PURPOSE:

Health-related quality of life (HRQoL) is an important endpoint in cancer clinical trials. Analysis of HRQoL longitudinal data is plagued by missing data, notably due to dropout. Joint models are increasingly receiving attention for modelling longitudinal outcomes and the time-to-dropout. However, dropout can be informative or non-informative depending on the cause.

METHODS:

We propose using a joint model that includes a competing risks sub-model for the cause-specific time-to-dropout. We compared a competing risks joint model (CR JM) that distinguishes between two causes of dropout with a standard joint model (SJM) that treats all the dropouts equally. First, we applied the CR JM and SJM to data from 267 patients with advanced oesophageal cancer from the randomized clinical trial PRODIGE 5/ACCORD 17 to analyse HRQoL data in the presence of dropouts unrelated and related to a clinical event. Then, we compared the models using a simulation study.

RESULTS:

We showed that the CR JM performed as well as the SJM in situations where the risk of dropout was the same whatever the cause. In the presence of both informative and non-informative dropouts, only the SJM estimations were biased, impacting the HRQoL estimated parameters.

CONCLUSION:

The systematic collection of the reasons for dropout in clinical trials would facilitate the use of CR JMs, which could be a satisfactory approach to analysing HRQoL data in presence of both informative and non-informative dropout. TRIAL REGISTRATION This study is registered with ClinicalTrials.gov, number NCT00861094.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Qual Life Res Assunto da revista: REABILITACAO / TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Qual Life Res Assunto da revista: REABILITACAO / TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França